Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

BLA Submitted to FDA for Subcutaneous Formulation of DARZALEX® Utilizing ENHANZE®

americanpharmaceuticalreviewJuly 16, 2019

Tag: FDA , Subcutaneous Formulation

PharmaSources Customer Service